Literature DB >> 17709396

Functional analysis of the transcription repressor PLU-1/JARID1B.

Angelo G Scibetta1, Samantha Santangelo, Julia Coleman, Debbie Hall, Tracy Chaplin, John Copier, Steve Catchpole, Joy Burchell, Joyce Taylor-Papadimitriou.   

Abstract

The PLU-1/JARID1B nuclear protein, which is upregulated in breast cancers, belongs to the ARID family of DNA binding proteins and has strong transcriptional repression activity. To identify the target genes regulated by PLU-1/JARID1B, we overexpressed or silenced the human PLU-1/JARID1B gene in human mammary epithelial cells by using adenovirus and RNA interference systems, respectively, and then applied microarray analysis to identify candidate genes. A total of 100 genes showed inversely correlated differential expression in the two systems. Most of the candidate genes were downregulated by the overexpression of PLU-1/JARID1B, including the MT genes, the tumor suppressor gene BRCA1, and genes involved in the regulation of the M phase of the mitotic cell cycle. Chromatin immunoprecipitation assays confirmed that the metallothionein 1H (MT1H), -1F, and -1X genes are direct transcriptional targets of PLU-1/JARID1B in vivo. Furthermore, the level of trimethyl H3K4 of the MT1H promoter was increased following silencing of PLU-1/JARID1B. Both the PLU-1/JARID1B protein and the ARID domain selectively bound CG-rich DNA. The GCACA/C motif, which is abundant in metallothionein promoters, was identified as a consensus binding sequence of the PLU-1/JARID1B ARID domain. As expected from the microarray data, cells overexpressing PLU-1/JARID1B have an impaired G(2)/M checkpoint. Our study provides insight into the molecular function of the breast cancer-associated transcriptional repressor PLU-1/JARID1B.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709396      PMCID: PMC2168894          DOI: 10.1128/MCB.00274-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  93 in total

1.  Induction of hepatic metallothionein by nonmetallic compounds associated with acute-phase response in inflammation.

Authors:  K S Min; Y Terano; S Onosaka; K Tanaka
Journal:  Toxicol Appl Pharmacol       Date:  1991-10       Impact factor: 4.219

2.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

3.  BRCA1 mutations in primary breast and ovarian carcinomas.

Authors:  P A Futreal; Q Liu; D Shattuck-Eidens; C Cochran; K Harshman; S Tavtigian; L M Bennett; A Haugen-Strano; J Swensen; Y Miki
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

4.  Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis.

Authors:  M Satoh; M G Cherian; N Imura; H Shimizu
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

5.  Increase in metallothionein produced by chemicals that induce oxidative stress.

Authors:  J W Bauman; J Liu; Y P Liu; C D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  1991-09-01       Impact factor: 4.219

6.  Alterations in cytoskeletal protein sulfhydryls and cellular glutathione in cultured cells exposed to cadmium and nickel ions.

Authors:  W Li; Y Zhao; I N Chou
Journal:  Toxicology       Date:  1993-01-29       Impact factor: 4.221

7.  Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; D T Bishop; S A Narod; D E Goldgar
Journal:  Lancet       Date:  1994-03-19       Impact factor: 79.321

8.  Collagen-induced rapid morphogenesis of human mammary epithelial cells: the role of the alpha 2 beta 1 integrin.

Authors:  F Berdichevsky; C Gilbert; M Shearer; J Taylor-Papadimitriou
Journal:  J Cell Sci       Date:  1992-07       Impact factor: 5.285

9.  The transcription factor MTF-1 is essential for basal and heavy metal-induced metallothionein gene expression.

Authors:  R Heuchel; F Radtke; O Georgiev; G Stark; M Aguet; W Schaffner
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

10.  cdc2 phosphorylation is required for its interaction with cyclin.

Authors:  B Ducommun; P Brambilla; M A Félix; B R Franza; E Karsenti; G Draetta
Journal:  EMBO J       Date:  1991-11       Impact factor: 11.598

View more
  65 in total

1.  A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Authors:  Alexander Roesch; Mizuho Fukunaga-Kalabis; Elizabeth C Schmidt; Susan E Zabierowski; Patricia A Brafford; Adina Vultur; Devraj Basu; Phyllis Gimotty; Thomas Vogt; Meenhard Herlyn
Journal:  Cell       Date:  2010-05-14       Impact factor: 41.582

Review 2.  Histone demethylases and cancer.

Authors:  Sotirios C Kampranis; Philip N Tsichlis
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

Review 3.  JARID1 Histone Demethylases: Emerging Targets in Cancer.

Authors:  Kayla M Harmeyer; Nicole D Facompre; Meenhard Herlyn; Devraj Basu
Journal:  Trends Cancer       Date:  2017-09-12

4.  Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).

Authors:  Ping-Pui Wong; Fabrizio Miranda; KaYi V Chan; Chiara Berlato; Helen C Hurst; Angelo G Scibetta
Journal:  Mol Cell Biol       Date:  2012-02-27       Impact factor: 4.272

5.  HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.

Authors:  I-Ju Yeh; Kyung Song; Bryan M Wittmann; Xiaodong Bai; David Danielpour; Monica M Montano
Journal:  Biochem J       Date:  2014-09-01       Impact factor: 3.857

6.  Transcription factors, coregulators, and epigenetic marks are linearly correlated and highly redundant.

Authors:  Tobias Ahsendorf; Franz-Josef Müller; Ved Topkar; Jeremy Gunawardena; Roland Eils
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

7.  JARID1B is a luminal lineage-driving oncogene in breast cancer.

Authors:  Shoji Yamamoto; Zhenhua Wu; Hege G Russnes; Shinji Takagi; Guillermo Peluffo; Charles Vaske; Xi Zhao; Hans Kristian Moen Vollan; Reo Maruyama; Muhammad B Ekram; Hanfei Sun; Jee Hyun Kim; Kristopher Carver; Mattia Zucca; Jianxing Feng; Vanessa Almendro; Marina Bessarabova; Oscar M Rueda; Yuri Nikolsky; Carlos Caldas; X Shirley Liu; Kornelia Polyak
Journal:  Cancer Cell       Date:  2014-06-16       Impact factor: 31.743

8.  Histone demethylase jumonji AT-rich interactive domain 1B (JARID1B) controls mammary gland development by regulating key developmental and lineage specification genes.

Authors:  Mike Ran Zou; Jian Cao; Zongzhi Liu; Sung Jin Huh; Kornelia Polyak; Qin Yan
Journal:  J Biol Chem       Date:  2014-05-06       Impact factor: 5.157

9.  Essential functions of the histone demethylase lid.

Authors:  Ling Li; Christina Greer; Robert N Eisenman; Julie Secombe
Journal:  PLoS Genet       Date:  2010-11-24       Impact factor: 5.917

10.  Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes.

Authors:  Yi Huang; Tracy Murray Stewart; Yu Wu; Stephen B Baylin; Laurence J Marton; Brandy Perkins; Richard J Jones; Patrick M Woster; Robert A Casero
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.